This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Tool In Allegro CTMS@Site Allows For Easy Tracking Of Patient Recruitment Initiatives

MADISON, Wis., Nov. 7, 2012 /PRNewswire/ -- The fall release of Allegro CTMS@Site, the clinical trial management system (CTMS) built for investigator sites and research groups, is rich with new features that aim to ease the workload of busy site staff.  One key enhancement, much-anticipated by prospects and customers alike, is the addition of patient recruitment campaign functionality.

(Logo: http://photos.prnewswire.com/prnh/20101118/CG04162)

Sites are faced with many options for patient recruitment.  Ads may be placed on media outlets such as TV and radio, social media may be utilized, or sites may develop their own call or email lists.  However, tracking the impact of the campaign, response rate, and actual enrollment from all these sources can be difficult.  Even more challenging, is comparing those numbers to the total cost of the recruitment effort and understanding which recruitment methods generate the highest return on investment (ROI).

The new recruitment campaign functionality within Allegro CTMS@Site helps ensure that the appropriate level of contact has been made and the next steps are clearly defined. Site staff can clearly see the recruitment progression from initial contact with a patient through registering them to the protocol.

In addition to traditional recruitment sources, Allegro CTMS@Site allows sites to leverage their existing patient registry to quickly and easily generate their own call or email lists for recruitment campaigns.  Within the patient registry, potential matches can be identified on a number of factors that are best suited to the requirements of the protocol.  By relying on their existing data, sites can spend their time reaching out to potential patients rather than gathering contact information.

With the addition of patient recruitment campaigns to the already highly adept CTMS, sites are able to streamline and simplify their workflows, increase efficiency, learn from their successes and failures, and ultimately increase their ROI. With a clear understanding of the number of potential subjects contacted versus the number enrolled on the trial and the resources spent, sites gain more visibility into negotiating future recruitment budgets.

Learn more about patient recruitment by downloading the solution brief.

About the Allegro Research on Demand Product LineThe Allegro ® family of products are easy-to-use, intuitively designed, cloud-based systems that support clinical research operations excellence. Allegro CTMS@Site ® is designed exclusively for investigator sites and research groups.

To set up a demonstration of Allegro CTMS@Site or to learn more, please contact Forte Research Systems.

SOURCE Forte Research Systems, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,584.33 +227.46 1.31%
S&P 500 2,043.49 +30.60 1.52%
NASDAQ 4,716.9290 +72.6170 1.56%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs